Andrew Ratz, Ph.D., was appointed Senior Vice President, Drug Development, Delivery and Device in January 2025, and Chief Technical Operations Officer in February 2026. He is responsible for leading the Company’s global technical development, manufacturing and supply chain functions, supporting Neurocrine’s expansion beyond small molecules into biologics and device-based therapies. Dr. Ratz joined Neurocrine after a nearly 30-year career at Eli Lilly, where he contributed to the development and successful registration of more than 25 products across multiple therapeutic areas and molecule modalities. From 2020 to 2024, he served as Senior Vice President, Delivery, Device and Connected Solutions at Eli Lilly, where he led the integrated design and development of devices, drug-device combination products, and packaging systems for both the biotech and small molecule portfolios. Prior to that, Dr. Ratz served as Senior Director of Process Chemistry and Chemical Engineering and Head of Global Outsourcing for Eli Lilly’s small molecule portfolio. Dr. Ratz holds a B.S. in Chemistry from Indiana University, as well as a Ph.D. in Chemistry from Harvard University.